Health news
Health news top Health news

   Login  |  Register    
Health News Make AMN Your Home PageDiscussion BoardsAdvanced Search ToolMedical RSS/XML News FeedHealth news
  You are here : Health.am > Health Centers > Cancer Health CenterCancer news

Aggressive cancer treated successfully in mice

Cancer newsMay 09, 2006

White blood cells from a strain of cancer-resistant mice cured advanced cancers in ordinary laboratory mice, researchers at Wake Forest University School of Medicine reported.

“Even highly aggressive forms of malignancy with extremely large tumors were eradicated,” Zheng Cui, M.D., Ph.D., and colleagues reported in this week’s on-line edition of Proceedings of the National Academy of Sciences.

The transplanted white blood cells not only killed existing cancers, but also protected normal mice from what should have been lethal doses of highly aggressive new cancers.

"This is the very first time that this exceptionally aggressive type of cancer was treated successfully,” said Cui. “Never before has this been done with any other therapy.”

The original studies on the cancer-resistant mice - reported in 2003 - showed that such resistance could be inherited, which had implications for inheritance of resistance in humans, said Mark C. Willingham, M.D., a pathologist and co-investigator. “This study shows that you can use this resistant-cell therapy in mice and that the therapy works. The next step is to understand the exact way in which it works, and perhaps eventually design such a therapy for humans.”

The cancer-resistant mice all stem from a single mouse discovered in 1999. “The cancer resistance trait so far has been passed to more than 2,000 descendants in 14 generations,” said Cui, associate professor of pathology. It also has been bred into three additional mouse strains. About 40 percent of each generation inherits the protection from cancer.

The original group of cancer-resistant mice, also described in Proceedings of the National Academy of Sciences, successfully fought off a range of virulent transplanted cancers.

“Now we know that we can take white blood cells from this strange mouse and put them into a normal mouse and these cells will still kill cancers,” said Willingham, professor of pathology and head of the Section on Tumor Biology. “This is therapy in a mouse that does not have this magical genetic inheritance.”

The transplanted white blood cells included natural killer cells, and other white blood cells called neutrophils and macrophages that are part of the body’s “innate immune system.” This system forms a first line of host defense against pathogens, such as bacteria.

“Their activation requires no prior exposure, but rather depends on a pre-determined mechanism to recognize specific patterns on the cancer cell surface,” the researchers said.

Moreover, preliminary studies show that the white blood cells also kill “endogenous” cancers - cancers that spring up naturally in the body’s own cells.

Cui and Willingham said the research produced many other surprises. For one thing, if a virulent tumor was planted in a normal mouse’s back, and the transplanted white blood cells were injected into the mouse’s abdomen, the cells still found the cancer without harming normal cells. The kind of cancer didn’t seem to matter.

A single injection of cancer-resistant macrophages offered long-term protection for the entire lifespan of the recipient mouse, something very unexpected, they said.

“The potency and selectivity for cancer cells are so high that, if we learned the mechanism, it would give us hope that this would work in humans,” said Cui. “This would suggest that cancer cells send out a signal, but normal white blood cells can’t find them.”

Cui said the findings “suggest a cancer-host relationship that may point in a new therapeutic direction in which adverse side effects of treatment are minimal.”

The next steps include understanding the molecular mechanism. “The real key is finding the mutation, which is an ongoing investigation in collaboration with several other laboratories,” said Willingham.

Cui, Willingham and their colleagues also showed that highly purified natural killer cells, macrophages and neutrophils taken from the cancer-resistant mice killed many different types of cancer cells in laboratory studies in test tubes.

Besides Cui and Willingham, the team includes Amy M. Hicks, Ph.D., Anne M. Sanders, B.S., Holly M. Weir, M.S., Wei Du, M.D., and Joseph Kim, B.A., from pathology, Greg Riedlinger, B.S., from cancer biology, Martha A. Alexander-Miller, Ph.D., from microbiology and immunology, Mark J. Pettenati, Ph.D., and C. Von Kap-Herr, M. Sc., from medical genetics, and Andrew J.G. Simpson, Ph.D., and Lloyd J. Old, M.D., of the Ludwig Institute for Cancer Research in New York.

http://www.wfubmc.edu

Provided by ArmMed Media
Revision date: July 7, 2011
Last revised: by Dave R. Roger, M.D.

Email this to a friend Bookmark this! Printable Version

RELATED STORIES:


 Comments [ + Post Your Own

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]




We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.

All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

Please enter the word you see in the image below:


   [advanced search]   
Interactive Quiz:
1. An infant who sits with only minimal support, attempts to attain a toy beyond reach, and rolls over from the supine to the prone position, but does not have a pincer grasp, is at a developmental level of
2 months
4 months
6 months
9 months
1 year



Health Centers

  Head and Neck Cancer

  Esophageal Cancer

  Benign Esophageal Tumors

  Cancer of the larynx

  Salivary Gland Tumors

  Cancer of the Hypopharynx

  Cancer of the Oropharynx

  Cancer of the Oral Cavity

  Cancer of the Nasal Cavity

  Head and Neck Cancer
      (- for profesionals -)


  Gynecologic cancers

  Cervical cancer

  Endometrial Cancer

  Fallopian Tube Cancer

  Ovarian Cancer

  Vaginal cancer

  Vulvar Cancer

  Ureteral & Renal Pelvic
  Cancers


  Uterine Cancer

  Gestational Trophoblastic
  Neoplasia


  Bladder cancer

  Breast cancer

  Colorectal Cancer

  Carcinoma of the Anus

  Anal Cancer Management

  Hodgkin's lymphoma

  Kaposi's sarcoma

  Kidney cancer

  Laryngeal cancer

  Liver cancer

  Lung cancer

  Lung cancer non small cell

  Lung cancer - small cell

  Oral cancer

  Osteosarcoma

  Cancer of the Penis

  Prostate cancer

  Skin cancer

  Stomach cancer

  Testicular cancer

» » »

Health Centers





Diabetes









Health news
  


Health Encyclopedia

Diseases & Conditions

Drugs & Medications

Health Tools

Health Tools



   Health newsletter

  





   Medical Links



   RSS/XML News Feed



   Feedback






Add to Google Reader or Homepage
Cancer: Overview, Causes, Risk Factors, Treatment
Add to My AOL




Human Rights in Patient Care - Practitioner Guide

hit counter